Evidence map›Paper›PMID 14627666›Full record

ArticleJournal of medical genetics2003

Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome.

N Diaz-Meyer, C D Day, K Khatod, E R Maher, W Cooper, W Reik, C Junien, G Graham, E Algar, V M Der Kaloustian and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of medical genetics, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 145 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. A mechanistic view of long noncoding RNAs in cancer.Wiley interdisciplinary reviews. RNA · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

N Diaz-MeyerDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
C D Day
K Khatod
E R Maher
W Cooper
W Reik
C Junien
G Graham
E Algar
V M Der Kaloustian
M J Higgins
Cancer Genetics (United States) · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
TUMOR SUPPRESSORS AND IMPRINTING AT CHROMOSOME 11P155R01CA063333 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HIGGINS, MICHAEL J · 1994 to 2000
$353k
NCI NIH HHS CA16056NCI NIH HHS CA63333
6 · The paper itself

Abstract

contextBeckwith-Wiedemann syndrome (BWS) arises by several genetic and epigenetic mechanisms affecting the balance of imprinted gene expression in chromosome 11p15.5. The most frequent alteration associated with BWS is the absence of methylation at the maternal allele of KvDMR1, an intronic CpG island within the KCNQ1 gene. Targeted deletion of KvDMR1 suggests that this locus is an imprinting control region (ICR) that regulates multiple genes in 11p15.5. Cell culture based enhancer blocking assays indicate that KvDMR1 may function as a methylation modulated chromatin insulator and/or silencer.

objectiveTo determine the potential consequence of loss of methylation (LOM) at KvDMR1 in the development of BWS.

methodsThe steady state levels of CDKN1C gene expression in fibroblast cells from normal individuals, and from persons with BWS who have LOM at KvDMR1, was determined by both real time quantitative polymerase chain reaction (qPCR) and ribonuclease protection assay (RPA). Methylation of the CDKN1C promoter region was assessed by Southern hybridisation using a methylation sensitive restriction endonuclease.

resultsBoth qPCR and RPA clearly demonstrated a marked decrease (86-93%) in the expression level of the CDKN1C gene in cells derived from patients with BWS, who had LOM at KvDMR1. Southern analysis indicated that downregulation of CDKN1C in these patients was not associated with hypermethylation at the presumptive CDKN1C promoter.

conclusionsAn epimutation at KvDMR1, the absence of maternal methylation, causes the aberrant silencing of CDKN1C, some 180 kb away on the maternal chromosome. Similar to mutations at this locus, this silencing may give rise to BWS.

Indexed as

DNA MethylationMembrane ProteinsBeckwith-Wiedemann SyndromeCell LineCyclin-Dependent Kinase Inhibitor p57Enzyme InhibitorsFibroblastsGene Expression RegulationGene SilencingGenomic ImprintingHumansNuclear ProteinsPotassium Channels, Voltage-GatedReverse Transcriptase Polymerase Chain ReactionRNA, Long NoncodingRNA, UntranslatedCDKN1C protein, humanCyclin-Dependent Kinase Inhibitor p57Enzyme InhibitorsKCNQ1OT1 long non-coding RNA, humanKCNQ1OT1 RNAMembrane ProteinsNuclear ProteinsPotassium Channels, Voltage-GatedRNA, Long NoncodingRNA, Untranslated

Identifiers

PMID14627666
PMCPMC1735305
OpenAlexW2110228320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.